Mathematical models of HIV pathogenesis and treatment

BioEssays

Volumn 24, Issue 12, 2002, Pages 1178-1187

  Wodarz, Dominik ^a   Nowak, Martin A ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ALGORITHM; ANIMAL; DISEASE COURSE; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; REVIEW; THEORETICAL MODEL; TIME; VIROLOGY;

ALGORITHMS; ANIMALS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; HIV; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; TIME FACTORS;

EID: 0036901603     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10196     Document Type: Review

References (42)

1. Nowak MA, Bangham CR. Population dynamics of immune responses to persistent viruses. Science 1996;272:74-79.
2. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natn Acad Sci USA 1997;94:6971-6976.
3. Wei XP, et al. Viral dynamics in human-immunodeficiency-virus type-1 infection. Nature 1995;373:117-122.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and Cd4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in-vivo - Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
6. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-191.
7. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
8. Klenerman P, Phillips RE, Rinaldo CR, Wahl LM, Ogg G, May RM, McMichael AJ, Nowak MA. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci USA 1996;93:15323-15328.
9. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-13197.
10. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994;94:2060-2067.
11. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. A new classification for HIV-1 [letter]. Nature 1998;391:240.
12. Callaway DS, Ribeiro RM, Nowak MA. Virus phenotype switching and disease progression in HIV-1 infection. Proc R Soc Lond B Biol Sci 1999;266:2523-2530.
13. Wodarz D, Nowak MA. The effect of different immune responses on the evolution of virulent CXCR4 tropic HIV Proc Roy Soc London, Series B 1998;265:2149-2158.
14. Wodarz D, Lloyd AL, Jansen VAA, Nowak MA. Dynamics of macrophage and T cell infection by HIV. J Theor Biol 1999;196:101-113.
15. Nowak MA, Anderson RM, McLean AR, Wolfs TFW, Goudsmit J. May RM. Antigenic diversity thresholds and the development of Aids. Science 1991;254:963-969.
16. Nowak MA, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-611.
17. Nowak MA, May RM. Virus Dynamics. Mathematical Principles of Immunology and Virology. Oxford: Oxford University Press; 2000.
18. Kaur A, Alexander L, Staprans SI, Denekamp L, Hale CL, McClure HM, Feinberg MB, Desrosiers RC, Johnson RP. Emergence of cytotoxic T lymphocyte escape mutations in nonpathogenic simian immunodeficiency virus infection Eur J Immunol 2001;31:3207-3217.
19. Broussard SR, Staprans SI, White R, Whitehead EM, Feinberg MB, Allan JS. Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol 2001;75:2262-2275.
20. Goldstein S, Ourmanov I, Brown CR, Beer BE, Elkins WR, Plishka R, Buckler-White A, Hirsch VM. Wide range of viral load in healthy african green monkeys naturally infected with simian immunodeficiency virus. J Virol 2000;74:11744-11753.
21. Wodarz D, Krakauer DC. Defining CTL-induced pathology: Implications for HIV. Virology 2000;274:94-104.
22. Schmitz JE, et al. Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes. Science 1999;283:857-860.
23. Jin X, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991-998.
24. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
25. Jeffery KJ, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999;96:3848-3853.
26. Saah AJ, et al. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort study. Aids 1998;12:2107-2113.
27. Wodarz D, Page KM, Arnaout RA, Thomsen AR, Lifson JD, Nowak MA. A new theory of cytotoxic T-lymphocyte memory: Implications for HIV treatment. Phil Trans R Soc Lond B Biol Sci 2000;355:329-343.
28. Wodarz D, May RM, Nowak MA. The role of antigen-independent persistence of memory CTL International Immunology 2000;12:467-477.
29. Thomsen AR, Johansen J, Marker O, Christensen JP. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC crass II-deficient mice and B cell- deficient mice. J Immunol 1996;157:3074-3080.
30. Thomsen AR, Nansen A, Christensen JP, Andreasen SO, Marker O. CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus. J Immunol 1998;161:4583-4590.
31. Borrow P, Tishon A, Lee S, Xu J, Grewal IS, Oldstone MB, Flavell RA. CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL. J Exp Med 1996;183:2129-2142.
32. Borrow P, Tough DF, Eto D, Tishon A, Grewal IS, Sprent J, Flavell RA, Oldstone MB. CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J Virol 1998;72:7440-7449.
33. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999;73:6721-6728.
34. Wodarz D, Nowak MA. Specific therapy regimes could lead to long-term control of HIV. Proc Natl Acad Sci USA 1999;96:14464-14469.
35. Lifson JD, et al. Containment of SIV infection: Cellular immune responses and protection from rechallenge following transient post-inoculation antiretroviral treatment. J Virol 2000;74:2584-2593.
36. Lifson JD, et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001;75:10187-10199.
37. Lisziewicz J, Lori F. Structured treatment interruptions in HIV/AIDS therapy. Microbes Infect 2002;4:207-214.
38. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, Lori F. Control of HIV despite the discontinuation of antiretroviral therapy [letter]. N Engl J Med 1999;340:1683-1684.
39. Montaner LJ. Structured treatment interruptions to control HIV-1 and limit drug exposure. Trends Immunol 2001;22:92-96.
40. Lori F, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000;290:1591-1593.
41. Ortiz GM, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 2001;98: 13288-13293.
42. Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. Aids 2000;14:2313-2322.